TG-2349

DRUG3 trials

Sponsors

TaiGen Biotechnology Co., Ltd., Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.

Conditions

Chronic Hepatics C Virus (HCV) Genotype 1CirrhosisHealthyHepatitis C, ChronicNon-CirrhoticTreatment naïve

Phase 1

A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients

CompletedNCT01523990

TaiGen Biotechnology Co., Ltd.Healthy, Hepatitis C, Chronic

Start: 2011-10-31End: 2013-07-31Updated: 2014-12-19

Phase 2

Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection

CompletedNCT02340962

TaiGen Biotechnology Co., Ltd.Hepatitis C, Chronic

Start: 2015-05-31End: 2016-10-26Updated: 2023-07-14

Phase 3

A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients

CompletedNCT04155515

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.Chronic Hepatics C Virus (HCV) Genotype 1, Cirrhosis, Non-Cirrhotic +1

Start: 2019-06-13End: 2020-08-11Updated: 2021-02-04